Key facts
- This page summarizes James M. Cornelius's Form 4 filing for MBX Biosciences, Inc. (MBX).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Sep 2024, 20:11.
James M. Cornelius - 16 Sep 2024 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)
- Reporting relationship
- Director
- Issuer ticker
- MBX
- Reported as of
- 16 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Sep 2024, 20:11:02 UTC
- Prior SEC filing
- 12 Sep 2024
- Next SEC filing
- 06 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Bartram, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James M. Cornelius filed Form 4 for MBX Biosciences, Inc. (MBX) on 17 Sep 2024.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MBX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +102,082
- Change %
- Price
- Shares after
- 102,082
- Date
- 16 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MBX
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -994,069
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 82,686
- Exercise price
- Footnotes
- F1
MBX
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -233,192
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,396
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.